RNA Technologies Empowering Small Molecule Therapeutics

Share this:
Published: 10 Aug 2018

This Drug Discovery TOE highlights the innovations in small molecule therapies targeting RNA. The key technology trends highlighted include in-silico assays, RNA drugs, nanoparticle delivery platforms, and a clinical trial summary of small molecule therapies targeting RNA. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: RNA-modifying enzymes, targeted small molecules, RNA therapy, short hairpin RNA, mRNA, RNAi, nanoparticle therapy, rare disease therapy, splicing


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..